子痫前期合并胎儿生长受限产妇的临床治疗价值 ?(1)
【摘要】 目的：探讨对子痫前期伴有胎儿生长受限患者采用低分子肝素+叶酸治疗后的临床价值。方法：选择和平县人民医院2016年4月-2019年3月收治的66例子痫前期伴有胎儿生长受限患者作为试验对象，通过数字奇偶法分为A组和B组，A组(n=33例)采用低分子肝素治疗方案，B组(n=33例)采用低分子肝素+叶酸治疗方案。对比两组产妇的分娩结局及新生儿系列指标水平。结果：B组剖宫产比例、早产比例及产后出血比例均低于A组，差异有统计学意义(P<0.05);B组新生儿腹围、头围、双顶径、股骨长度、体质量及胎盘质量均高于A组，差异有统计学意义(P<0.05)。结论：子痫前期伴有胎儿生长受限患者临床接受低分子肝素+叶酸治疗，降低了剖宫产比例、早产比例及产后出血比例，有利于腹围、头围、双顶径、股骨长度、体质量及胎盘质量的提升，为子痫前期伴有胎儿生长受限患者的疾病转归奠定了基础。
【关键词】 低分子肝素 叶酸 子痫前期 胎儿生长受限 产妇分娩结局 新生儿指标
[Abstract] Objective： To investigate the clinical experience of Low Molecular Weight Heparin combined with Folic Acid in patients with preeclampsia and fetal growth restriction. Method： A total of 66 patients with preeclampsia and fetal growth restriction were selected from People’s Hospital of Heping County from April 2016 to March 2019. The patients were divided into group A and group B by digital parity method， patients in group A (n=33 patients) were treated with Low Molecular Weight Heparin， and patients in group B (n=33 patients) were treated with Low Molecular Weight Heparin combined with Folic Acid. The maternal outcomes and neonatal series of indicators were compared between the two groups. Result： The proportion of cesarean section， preterm birth rate and postpartum hemorrhage in group B were lower than those in group A (P<0.05). The neonatal abdominal circumference， head circumference， biparietal diameter， femur length， body mass and placental mass of patients in group B were higher than those of group A， and the differences were statistically significant (P<0.05). Conclusion： Patients with preeclampsia and fetal growth restriction receive Low Molecular Weight Heparin combined with Folic Acid treatment， which reduces the proportion of cesarean section， the proportion of premature delivery and the proportion of postpartum hemorrhage， which is beneficial to abdominal circumference， head circumference， double top diameter， femur length and body. The improvement in quality and placental quality laid the foundation for the disease outcome of patients with preeclampsia and fetal growth restriction.
據不完全统计，孕产妇众多疾病中，子痫前期的发病率较高，且对于子痫前期患者而言，临床表现为胎儿生长受限，并且有明显上升的趋势，对此临床确定有效方法对子痫前期伴有胎儿生长受限患者展开及时治疗，意义显著[1-2]。本次研究将针对子痫前期伴有胎儿生长受限患者探究低分子肝素+叶酸药物治疗的可行性，以利于产妇分娩结局及新生儿指标的改善。
1 资料与方法
1.1 一般资料
选择和平县人民医院2016年4月-2019年3月收治的66例子痫前期伴有胎儿生长受限患者作为试验对象，纳入标准：患者对于低分子肝素及叶酸未表现出用药禁忌证。排除标准：(1)凝血功能异常;(2)有呼吸系统疾病;(3)有慢性高血压疾病;(4)有严重内分泌疾病。通过数字奇偶法分为A组和B组，A组(n=33例)：年龄22～39岁，平均(29.49±0.35)岁;孕周28～36周，平均(31.13±0.69)周;B组(n=33例)：年龄23～41岁，平均(29.53±0.39)岁;孕周29～37周，平均(31.19±0.52)周;观察对比两组年龄、孕周，差异无统计学意义(P>0.05)。本研究患者签署知情同意书，经伦理委员会批准。, 百拇医药(李翅)
【关键词】 低分子肝素 叶酸 子痫前期 胎儿生长受限 产妇分娩结局 新生儿指标
[Abstract] Objective： To investigate the clinical experience of Low Molecular Weight Heparin combined with Folic Acid in patients with preeclampsia and fetal growth restriction. Method： A total of 66 patients with preeclampsia and fetal growth restriction were selected from People’s Hospital of Heping County from April 2016 to March 2019. The patients were divided into group A and group B by digital parity method， patients in group A (n=33 patients) were treated with Low Molecular Weight Heparin， and patients in group B (n=33 patients) were treated with Low Molecular Weight Heparin combined with Folic Acid. The maternal outcomes and neonatal series of indicators were compared between the two groups. Result： The proportion of cesarean section， preterm birth rate and postpartum hemorrhage in group B were lower than those in group A (P<0.05). The neonatal abdominal circumference， head circumference， biparietal diameter， femur length， body mass and placental mass of patients in group B were higher than those of group A， and the differences were statistically significant (P<0.05). Conclusion： Patients with preeclampsia and fetal growth restriction receive Low Molecular Weight Heparin combined with Folic Acid treatment， which reduces the proportion of cesarean section， the proportion of premature delivery and the proportion of postpartum hemorrhage， which is beneficial to abdominal circumference， head circumference， double top diameter， femur length and body. The improvement in quality and placental quality laid the foundation for the disease outcome of patients with preeclampsia and fetal growth restriction.
據不完全统计，孕产妇众多疾病中，子痫前期的发病率较高，且对于子痫前期患者而言，临床表现为胎儿生长受限，并且有明显上升的趋势，对此临床确定有效方法对子痫前期伴有胎儿生长受限患者展开及时治疗，意义显著[1-2]。本次研究将针对子痫前期伴有胎儿生长受限患者探究低分子肝素+叶酸药物治疗的可行性，以利于产妇分娩结局及新生儿指标的改善。
1 资料与方法
1.1 一般资料
选择和平县人民医院2016年4月-2019年3月收治的66例子痫前期伴有胎儿生长受限患者作为试验对象，纳入标准：患者对于低分子肝素及叶酸未表现出用药禁忌证。排除标准：(1)凝血功能异常;(2)有呼吸系统疾病;(3)有慢性高血压疾病;(4)有严重内分泌疾病。通过数字奇偶法分为A组和B组，A组(n=33例)：年龄22～39岁，平均(29.49±0.35)岁;孕周28～36周，平均(31.13±0.69)周;B组(n=33例)：年龄23～41岁，平均(29.53±0.39)岁;孕周29～37周，平均(31.19±0.52)周;观察对比两组年龄、孕周，差异无统计学意义(P>0.05)。本研究患者签署知情同意书，经伦理委员会批准。, 百拇医药(李翅)
参见：首页 > 保健版 > 家庭健康 > 女性保健 > 孕育新生命 > 胎儿知识